1
|
Patrikainen MS, Pan P, Barker HR, Parkkila S. Altered gene expression in the lower respiratory tract of Car6 (-/-) mice. Transgenic Res 2016; 25:649-64. [PMID: 27209317 DOI: 10.1007/s11248-016-9961-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2015] [Accepted: 05/13/2016] [Indexed: 12/13/2022]
Abstract
From birth, the respiratory tract mucosa is exposed to various chemical, physical, and microbiological stress factors. Efficient defense mechanisms and strictly regulated renewal systems in the mucosa are thus required. Carbonic anhydrase VI (CA VI) is the only secreted isoenzyme of the α-CA gene family. It is transported in high concentrations in saliva and milk into the alimentary tract where it contributes to optimal pH homeostasis. Earlier study of transcriptomic responses of Car6 (-/-) mice has shown changes in the response to oxidative stress and brown fat cell differentiation in the submandibular gland. It has been suggested that CA VI delivered to the mucosal surface of the bronchiolar epithelium is an essential factor in defense and renewal of the lining epithelium. In this study, the transcriptional effects of CA VI deficiency were investigated in both trachea and lung of Car6 (-/-) mice using a cDNA microarray analysis. Functional clustering of the results indicated significant changes of gene transcription in the lower airways. The altered biological processes included antigen transport by M-cells, potassium transport, muscle contraction, and thyroid hormone synthesis. Immunohistochemical staining confirmed the absence of CA VI in the submandibular gland of Car6 (-/-) mice. Immunostaining of the trachea and lung samples revealed no differences between the knockout and wild type groups nor were any morphological changes observed. The present findings can help us to recognize novel functions for CA VI-one of the major protein constituents of saliva and milk.
Collapse
Affiliation(s)
| | - Peiwen Pan
- School of Medicine, University of Tampere, 33014, Tampere, Finland.,Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA
| | - Harlan R Barker
- School of Medicine, University of Tampere, 33014, Tampere, Finland
| | - Seppo Parkkila
- School of Medicine, University of Tampere, 33014, Tampere, Finland.,Fimlab Ltd, Tampere University Hospital, 33520, Tampere, Finland
| |
Collapse
|
2
|
Guenther-Yenke CL, McKiernan BC, Papich MG, Powell E. Pharmacokinetics of an extended-release theophylline product in cats. J Am Vet Med Assoc 2007; 231:900-6. [PMID: 17867974 DOI: 10.2460/javma.231.6.900] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To evaluate the pharmacokinetics of a brand of extended-release theophylline tablets and capsules in healthy cats. DESIGN Randomized 3-way crossover study. ANIMALS 6 healthy cats. PROCEDURES A single dose of aminophylline (10 mg/kg [4.5 mg/lb], IV), a 100-mg extended-release theophylline tablet, or a 125-mg extended-release theophylline capsule was administered to all cats. Plasma samples were collected via preplaced central catheters throughout a 36-hour period. Plasma samples were frozen until analyzed by use of a fluorescence polarization monoclonal immunoassay. RESULTS All cats tolerated drug administration and plasma collection with no adverse effects. Peak concentrations were reached for both orally administered products between 8 and 12 hours after administration. Bioavailability was excellent. Plasma concentrations were within the human therapeutic concentration of 5 to 20 microg/mL. CONCLUSIONS AND CLINICAL RELEVANCE Daily administration of the brand of theophylline tablets and capsules used in this study at 15 mg/kg (6.8 mg/lb) and 19 mg/kg (8.6 mg/lb), respectively, maintained plasma concentrations within the desired therapeutic range in healthy cats.
Collapse
Affiliation(s)
- Christine L Guenther-Yenke
- Wheat Ridge Veterinary Specialists, Wheat Ridge Animal Hospital, 3695 Kipling St, Wheat Ridge, CO 80033, USA
| | | | | | | |
Collapse
|
3
|
Lewis MJ, Short AL, Lewis KE. Autonomic nervous system control of the cardiovascular and respiratory systems in asthma. Respir Med 2006; 100:1688-705. [PMID: 16524708 DOI: 10.1016/j.rmed.2006.01.019] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2005] [Revised: 01/19/2006] [Accepted: 01/25/2006] [Indexed: 12/01/2022]
Abstract
Patients with asthma have exaggerated bronchoconstriction of their airways in response to certain indirect (e.g. cold air, allergens, dust, exercise) or direct (e.g. inhaled methacholine) stimuli. This 'hyper-reactivity' usually co-exists with airway inflammation, although the pathophysiological mechanisms underlying these changes are not fully understood. It is likely that this hyper-reactivity is associated with abnormal autonomic nervous system (ANS) control. In particular, the parasympathetic (vagal) component of the ANS appears to be implicated in the pathogenesis of asthma. In addition, several studies have suggested the existence of differential alteration in ANS function following exercise in asthmatics compared with non-asthmatic individuals. Several early studies suggested that the altered autonomic control of airway calibre in asthma might be reflected by a parallel change in heart rate. Cardiac vagal reactivity does indeed appear to be increased in asthma, as demonstrated by the cardiac response to various autonomic functions tests. However, other studies have reported a lack of association between bronchial and cardiac vagal tone, and this is in accord with the concept of system-independent ANS control. This review provides a discussion of cardiovascular-autonomic changes associated with either the pathophysiology of asthma per se or with asthma pharmacotherapy treatment. Previous investigations are summarised suggesting an apparent association between altered autonomic-cardiovascular control and bronchial asthma. The full extent of autonomic dysfunction, and its clinical implications, has yet to be fully determined and should be the subject of future investigation.
Collapse
Affiliation(s)
- M J Lewis
- Department of Sports Science, University of Wales Swansea, Singleton Park, Swansea SA2 8PP, UK.
| | | | | |
Collapse
|
4
|
Kanda A, Yanai M, Suzuki T, Ohrui T, Sasaki H. Nocturnal wheeze in asthmatic patients. Chest 2000; 118:278. [PMID: 10893403 DOI: 10.1378/chest.118.1.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Sexton DL, Stephanie RN, Calcasola SL, Bottomley SR, Funk M. Adults' experience with asthma and their reported uncertainty and coping strategies. CLIN NURSE SPEC 1999; 13:8-14; quiz 15-7. [PMID: 10335144 DOI: 10.1097/00002800-199901000-00005] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This study examined the uncertainty experienced by persons with asthma and the coping strategies they used. The sample of 99 adults was interviewed by the investigators. Subjects responded to demographic and illness-related questions and completed the Mishel Uncertainty in Illness Scale and the Jalowiec Coping Scale. Subjects who had asthma for a longer duration reported lower levels of uncertainty. Those who were hospitalized because of asthma and those for whom pollen was a trigger experienced greater uncertainty. Females, individuals who went to an emergency department because of asthma, and those who attended pulmonary support groups used more coping strategies. Understanding the sources of perceived uncertainty may assist individuals to cope with and manage the chronic and acute phases of asthma.
Collapse
Affiliation(s)
- D L Sexton
- Adult Advanced Practice Nursing Program at Yale University School of Nursing, USA
| | | | | | | | | |
Collapse
|
6
|
ten Hacken NH, Postma DS, Bosma F, Drok G, Rutgers B, Kraan J, Timens W. Vascular adhesion molecules in nocturnal asthma: a possible role for VCAM-1 in ongoing airway wall inflammation. Clin Exp Allergy 1998; 28:1518-25. [PMID: 10024223 DOI: 10.1046/j.1365-2222.1998.00426.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Increased airway inflammation at night is thought to be one of the underlying mechanisms in nocturnal asthma. Vascular adhesion molecules may be important for the recruitment of inflammatory cells in the process of asthmatic airway inflammation. OBJECTIVE To determine the possible role of vascular adhesion molecules in increased airway inflammation at night in subjects with nocturnal asthma. METHODS Bronchial biopsies were obtained at 16.00 h and 04.00 h from 13 healthy controls, 15 asthmatic patients with PEF variation < or = 15% and 10 asthmatic patients with PEF variation > 15%. Biopsies were snap-frozen and double-immunostained for CD31 in combination with P-selectin, E-selectin, ICAM-1 or VCAM-1. RESULTS No significant day-night differences in expression of adhesion molecules were found in any of the three groups. The percentage of VCAM-1 positive vessels in biopsies of asthmatic patients was higher than in biopsies of healthy controls: 5.8 vs 2.5% (P < 0.05) at 16.00h and 11 vs 0% (P<0.05) at 04.00 h. In asthma, VCAM-1 expression was correlated with the number of EG2 positive cells: at 16.00 h (rho = 0.57, P < 0.01) as well as at 04.00 h (rho = 0.64, P< 0.01). Moreover, VCAM-1 expression was correlated with the number of CD25 positive cells at 16.00 h (rho = 0.43, P < 0.05) and at 04.00 h (rho = 0.41, P < 0.05). CONCLUSION Increased nocturnal airway obstruction in asthma is not associated with an increased nocturnal expression of vascular E-selectin, P-selectin, ICAM-1 or VCAM-1. The relationship between vascular VCAM-1 expression and sub-mucosal EG2 and CD25 positive cells, both at 16.00 h and 04.00 h, suggests a role for VCAM-1 in the ongoing airway wall inflammation of asthma.
Collapse
Affiliation(s)
- N H ten Hacken
- Department of Pulmonology, University Hospital Groningen, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
7
|
Jarjour NN, Lacouture PG, Busse WW. Theophylline inhibits the late asthmatic response to nighttime antigen challenge in patients with mild atopic asthma. Ann Allergy Asthma Immunol 1998; 81:231-6. [PMID: 9759799 DOI: 10.1016/s1081-1206(10)62817-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
BACKGROUND Inhaled antigen at night causes a more pronounced late asthmatic response (LAR) when compared with daytime challenges. Chronopharmacology with controlled-release theophylline given in the evening leads to a peak serum theophylline concentration (STC) in early morning which coincides with LAR that follows an evening challenge. OBJECTIVE To evaluate the effect of controlled-release theophylline given with the evening meal on the immediate asthmatic response (IAR) and LAR following nighttime antigen challenge in patients with mild atopic asthma. METHODS To qualify, subjects underwent antigen bronchoprovocation by graded nebulization until the IAR (fall in FEV1 of > or =20%) occurred; spirometry was then measured hourly for 8 hours to establish the presence of LAR (fall in FEV1 > or =15%). After 2 weeks of randomized, double-blind crossover treatment with either theophylline (target STC of 10 to 15 mg/L, (56 to 83 micromol/L)) or placebo, inhaled antigen challenge was performed at 10 PM in each subject. FEV1 values were measured immediately and then hourly for 8 hours following antigen challenge. RESULTS Twelve subjects completed the study. During the placebo phase, the maximal fall in FEV1 during LAR was 39 +/- 3% (mean +/- SEM) compared with 31 +/- 4% fall during theophylline treatment phase (P = .01). A reduction in LAR occurred despite higher dose (P <.05) of inhaled antigen during theophylline phase, which would have been expected to result in a more pronounced LAR. Serum theophylline concentration at 8 AM on the day following antigen challenge was 9.6 +/- 1.1 mg/L (53 +/- 6 micromol/L). CONCLUSION Nocturnal administration of controlled-release theophylline increases the tolerance to inhaled antigen and reduces severity of LAR. Because the LAR is linked to airway inflammation, these data support the possibility of antiinflammatory effects associated with theophylline use.
Collapse
Affiliation(s)
- N N Jarjour
- Department of Medicine, University of Wisconsin-Madison Medical School, USA
| | | | | |
Collapse
|
8
|
Seery JP, Janes SM, Ind PW, Datta AK. Circadian rhythm of cutaneous hypersensitivity reactions in nocturnal asthma. Ann Allergy Asthma Immunol 1998; 80:329-32. [PMID: 9564983 DOI: 10.1016/s1081-1206(10)62978-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Diurnal variation in mast cell discharge may play a central role in the early morning fall in peak expiratory flow rate (PEFR) in nocturnal asthmatic patients. METHODS We tested the hypothesis that there is a circadian rhythm in mast cell response to allergen in 15 patients with nocturnal asthma by measuring the magnitude of cutaneous hypersensitivity reactions at 0600, 1200, 1800, and 2400 hours. Pre-admission, prick skin testing on the ventral aspect of the forearm to various allergens was performed. The allergen producing the largest wheal was tested at six sites on one forearm. Response was quantified after 20 minutes by measuring the area of the wheal produced using planimetry. Every six hours the skin testing was repeated at six new sites on alternating forearms. The average area of the six wheals was calculated and recorded at each time. The prick skin technique was used at all times. RESULTS Maximal reactions occurred in 10 of the 15 patients at noon (P = .031, Friedman's two way analysis of variance). In these 10 patients wheal area at the time of maximum reactivity was on average 3.3-fold higher than at the time of minimum reactivity. The mean wheal areas for all 15 patients at 0600, 1200, 1800, and 2400 hours were 34 mm2, 42 mm2, 34 mm2, and 35 mm2 respectively. CONCLUSIONS These observations support the concept of a circadian rhythm in mast cell activity in patients with severe nocturnal asthma.
Collapse
Affiliation(s)
- J P Seery
- MRC Centre for Brain Repair and Academic Neurosurgery, Addenbrookes Hospital, Cambridge, England
| | | | | | | |
Collapse
|
9
|
Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995; 95:1635-41. [PMID: 7706471 PMCID: PMC295666 DOI: 10.1172/jci117838] [Citation(s) in RCA: 314] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Nocturnal asthma represents a unique subset of patients with asthma who experience worsening symptoms and airflow obstruction at night. The basis for this phenotype of asthma is not known, but beta 2-adrenergic receptors (beta 2AR) are known to downregulate overnight in nocturnal asthmatics but not normal subjects or nonnocturnal asthmatics. We have recently delineated three polymorphic loci within the coding block of the beta 2AR which alter amino acids at positions 16, 27, and 164 and impart specific biochemical and pharmacologic phenotypes to the receptor. In site-directed mutagenesis/recombinant expression studies we have found that glycine at position 16 (Gly16) imparts an accelerated agonist-promoted downregulation of beta 2AR as compared to arginine at this position (Arg16). We hypothesized that Gly16 might be overrepresented in nocturnal asthmatics and thus determined the beta 2AR genotypes of two well-defined asthmatic cohorts: 23 nocturnal asthmatics with 34 +/- 2% nocturnal depression of peak expiratory flow rates, and 22 nonnocturnal asthmatics with virtually no such depression (2.3 +/- 0.8%). The frequency of the Gly16 allele was 80.4% in the nocturnal group as compared to 52.2% in the nonnocturnal group, while the Arg16 allele was present in 19.6 and 47.8%, respectively. This overrepresentation of the Gly16 allele in nocturnal asthma was significant at P = 0.007 with an odds ratio of having nocturnal asthma and the Gly16 polymorphism being 3.8. Comparisons of the two cohorts as to homozygosity for Gly16, homozygosity for Arg16, or heterozygosity were also consistent with segregation of Gly16 with nocturnal asthma. There was no difference in the frequency of polymorphisms at loci 27 (Gln27 or Glu27) and 164 (Thr164 or Ile164) between the two groups. Thus the Gly16 polymorphism of the beta 2AR, which imparts an enhanced downregulation of receptor number, is overrepresented in nocturnal asthma and appears to be an important genetic factor in the expression of this asthmatic phenotype.
Collapse
Affiliation(s)
- J Turki
- Department of Medicine (Pulmonary), University of Cincinnati College of Medicine, Ohio 45267-0564, USA
| | | | | | | | | |
Collapse
|
10
|
Abstract
The prevalence of nocturnal asthma and its relationship with clinical features of the disease were studied in 150 consecutive patients. Nearly three-fourths of patients had nocturnal symptoms of asthma, either currently or in the past. There was no relation between the tendency to develop nocturnal symptoms and age, sex, atopic status, or periodicity of the disease. However, those with more severe asthma had a greater tendency to develop nocturnal symptoms. Patients currently having nocturnal symptoms had a poorer lung function.
Collapse
Affiliation(s)
- S K Chhabra
- Department of Cardiorespiratory Physiology, Vallabhbhai Patel Chest Institute, University of Delhi, India
| |
Collapse
|
11
|
Postma DS, Oosterhoff Y, van Aalderen WM, Kauffman HF, Wempe JB, Koëter GH. Inflammation in nocturnal asthma? Am J Respir Crit Care Med 1994; 150:S83-6. [PMID: 7952600 DOI: 10.1164/ajrccm/150.5_pt_2.s83] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
At present there is some indirect evidence for increased nocturnal inflammation in patients suffering from nocturnal asthma: 1. Circulating eosinophil numbers and activation, as reflected by increased levels of ECP and EDN and low-density eosinophils, are increased at night. 2. Circulating histamine levels are increased at night. 3. Hyperresponsiveness to AMP at night is increased compared with hyperresponsiveness to methacholine. However, most results of various studies point to nocturnal asthma's being an expression of more severe asthma: 1. Both AMP and propranolol responsiveness, indirect measures of airway hyperresponsiveness, are lower both at 4:00 A.M. and 4:00 P.M. in asthmatics with nocturnal asthma than those without nocturnal asthma. 2. Patients with nocturnal asthma have higher circulating numbers of eosinophils at both 4:00 A.M. and 4:00 P.M. than those without nocturnal asthma, and eosinophil survival is not different at these times. 3. Patients with nocturnal asthma have higher PGD2 levels in BAL both at 4:00 A.M. and 4:00 P.M. than those without nocturnal asthma, but show no significant difference between levels at these two times. 4. Two studies have shown no difference in BAL eosinophil numbers and activation parameters at night in nocturnal asthma. 5. Histamine levels in BAL fluid are comparable day and night in patients with and without nocturnal asthma. 6. Inflammatory mediators in BAL are higher in asthmatic patients than in normal subjects, but are not different between patients with and without nocturnal asthma. Thus, patients with nocturnal asthmatic symptoms show an overall increased burden of mediators released from mast cells and other inflammatory cells. In conclusion, we feel that the term "nocturnal asthma" is misleading, in that it does not describe a unique entity in certain patients with asthma. We prefer, in view of the previous arguments, to consider nocturnal asthma a mere expression of more severe asthma. Thus we suggest the term "nocturnal asthma" be changed to "asthma with nocturnal symptoms."
Collapse
Affiliation(s)
- D S Postma
- Department of Pulmonology, Allergy, and Pediatric Pulmonology University Hospital, Groningen, The Netherlands
| | | | | | | | | | | |
Collapse
|
12
|
Affiliation(s)
- E J Weersink
- Department of Pulmonology, University Hospital Groningen, The Netherlands
| | | |
Collapse
|
13
|
Rabe KF, Jörres R, Nowak D, Behr N, Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. THE AMERICAN REVIEW OF RESPIRATORY DISEASE 1993; 147:1436-41. [PMID: 8503554 DOI: 10.1164/ajrccm/147.6_pt_1.1436] [Citation(s) in RCA: 119] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The recent development of new beta 2-adrenoceptor agonists with a duration of action in excess of 12 h may change strategies in the treatment of bronchial asthma. This study aims at the direct comparison of the main representatives of this new class of drugs, formoterol (F) and salmeterol (S), in asthmatic patients over the course of 24 h. Twelve patients with mild bronchial asthma participated in a double-blind, randomized, placebo-controlled clinical trial. In a dose-finding study we determined the protective and bronchodilating effects of 12 and 24 micrograms F aerosol vs 50 and 100 micrograms S 30 min after inhalation. In a 24-h study we investigated the effects of 12 micrograms F and 50 micrograms S on airway tone and responsiveness. Bronchial responsiveness was assessed as the dose of methacholine necessary to decrease FEV1 by 20%. In the dose-finding study, compared with placebo, all doses of F and S equally increased FEV1 (p < 0.003) and protected against inhaled methacholine (p < 0.0001). In the 24-h study 12 micrograms F and 50 micrograms S increased FEV1 and significantly protected against methacholine-induced bronchoconstriction up to 24 h (p < 0.05), compared with placebo. Phase and amplitude of the circadian variation of FEV1 and airway responsiveness were not affected. Clinically recommended doses of aerosolized F (12 micrograms) and S (50 micrograms) have a duration of action up to 24 h and are equally effective at bronchodilation and protection in acute experiments in patients with mild bronchial asthma.
Collapse
Affiliation(s)
- K F Rabe
- Krankenhaus Grosshansdorf, Germany
| | | | | | | | | |
Collapse
|
14
|
Oosterhoff Y, Koëter GH, De Monchy JG, Postma DS. Circadian variation in airway responsiveness to methacholine, propranolol, and AMP in atopic asthmatic subjects. THE AMERICAN REVIEW OF RESPIRATORY DISEASE 1993; 147:512-7. [PMID: 8442580 DOI: 10.1164/ajrccm/147.3.512] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Increased airway hyperresponsiveness is thought to be one of the phenomena underlying nocturnal airway obstruction in asthma. To investigate the mechanisms that influence and modulate this phenomenon, we compared circadian variations in airway responsiveness with AMP and propranolol with the circadian variation in airway responsiveness to methacholine. Inhalation provocation tests were performed at 16.00 and 04.00 h in 16 nonsmoking atopic asthmatic subjects (18 to 42 yr of age), prospectively assigned to Group 1 (mean circadian peak expiratory flow rate [PEFR] variation > or = 15%) and Group 2 (< 15%). The circadian change in airway responsiveness to AMP, in contrast to methacholine, was significantly related to the circadian PEFR-variation of the 16 subjects (r = 0.81, p < 0.001). In Group 1 (n = 7) geometric mean PC20 AMP decreased more than PC20 methacholine during the night (2.3 and 0.9 doubling concentrations respectively, p < 0.05), whereas no difference in baseline FEV1 was found at the same time points during the different study days. Geometric mean PC20 propranolol did not change during the night. Daytime PC20 propranolol and PC20 AMP, in contrast to PC20 methacholine, were significantly lower in Group 1 as compared with Group 2. Together, the results show a higher susceptibility to stimulation of "indirect" airway responsiveness in the subjects with increased circadian PEFR amplitude. This suggests that mast cell activation rather than primary changes in smooth muscle cell contraction may play a role in the development of nocturnal airway obstruction.
Collapse
Affiliation(s)
- Y Oosterhoff
- Department of Pulmonology, University Hospital, Groningen, The Netherlands
| | | | | | | |
Collapse
|
15
|
Goldenheim PD, Schein LK. Chronotherapy of reversible airways disease with once-daily evening doses of a controlled-release theophylline preparation. Ann N Y Acad Sci 1991; 618:490-503. [PMID: 2006803 DOI: 10.1111/j.1749-6632.1991.tb27267.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
1. Asthma and COPD worsen at night and in the early morning, due to various circadian influences. 2. Uninterrupted sleep, stable lung function over 24 h, and reduced and stable airways responsiveness are primary therapeutic goals in asthma and COPD. 3. Once-daily evening theophylline chronotherapy meets these goals, providing rising blood levels at night and in the early morning, when most needed. 4. This regimen is now indicated for morning and evening dosing for reversible airway obstruction, in the United States and Canada, and marks the first available treatment for these diseases to include dosing time in the therapeutic strategy. It reflects increasing recognition by the medical community of the need to consider the individual patient's timing of symptoms in relation to the kinetics of the drug. 5. Theophylline chronotherapy is as well tolerated as more frequently administered methylxanthine preparations despite the relatively large single doses required by the prolonged dosing interval. The convenience of once-daily administration favors drug-taking compliance. 6. Theophylline chronotherapy does not provide constant blood levels over the 24-h day. Indeed, by improving lung function by means of a larger peak-to-trough difference than associated with twice-daily theophylline, once-daily chronotherapy has altered our thinking about theophylline pharmacodynamics.
Collapse
|